Straits Research Pvt Ltd
Canine Atopic Dermatitis Market Size is projected to reach USD 5.69 Billion by 2030, growing at a CAGR of 16.5%: Straits Research
August 03, 2022 12:30 ET | Straits Research
New York, United States, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Canine Atopic Dermatitis is marked by skin irritation that lasts for a long time and a particular pattern of skin lesions. IgE antibodies...
Logo.jpg
Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors
June 16, 2022 09:50 ET | Curative Biotechnology, Inc. 
Appointment of Independent Director Builds Upon Biotech Expertise Boca Raton, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a...
Picture1.jpg
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
June 15, 2022 07:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
Qualigen-Logo-Tag.png
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 20, 2022 09:15 ET | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
POWERHOUSE AESTHETIC BRANDS ALIGN TO LAUNCH A NATIONWIDE PREVENTATIVE SKIN HEALTH PROTOCOL EXPERIENCE
May 02, 2022 08:45 ET | Colorescience
Phoenix, AZ, May 02, 2022 (GLOBE NEWSWIRE) -- Know Better Skin this Summer with Colorescience®, a leader in advanced skin protection technology, and Aesthetics Biomedical®, a leader in novel...
Qualigen-Logo-Tag.png
Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®
April 05, 2022 09:15 ET | Qualigen Therapeutics, Inc.
Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
respirerx.jpg
RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmacoresistant Epilepsy and Chronic Pain
January 24, 2022 07:00 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Logo.jpg
Invectys to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference
January 06, 2022 09:00 ET | Invectys, Inc.
Houston, Texas, USA, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Invectys Inc. will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022.  Praveen Tyle, Ph.D., Invectys Inc....
respirerx.jpg
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury
November 29, 2021 08:45 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
TH_logo_couleur.png
Triple Hair Group renforce son conseil d'administration par l'ajout de compétences dans le domaine des marchés financiers et des sciences de la vie
November 29, 2021 08:00 ET | Triple Hair Inc.
MONTRÉAL, 29 nov. 2021 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. (« Triple Hair » ou la « Société »), une société spécialisée dans le développement de traitements novateurs pour lutter contre...